Curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and CIART, AFP-L3 and GP73
10.12092/j.issn.1009-2501.2020.07.006
- VernacularTitle: 雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART,AFP-L3,GP73的影响
- Author:
Gaoqing WANG
1
Author Information
1. Department of Hepatobiliary Surgery, Ningbo Medical Center Li Huili Hospital
- Publication Type:Journal Article
- Keywords:
Diurnal transcription repressor;
Fetal protein heterosomes;
Golgi membrane protein-73;
Hepatectomy;
Laparoscope;
Liver function;
Primary liver cancer;
Retitrix
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(7):752-756
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To study the curative efficacy of retetrexel combined with laparoscopic hepatectomy in treatment of patients with primary liver cancer and its effects on liver function and the effects of diurnal transcription suppressor (CIART), fetoprotein heterosomes (AFP-l3), golgi membrane protein-73 (GP73). METHODS: A total of 100 patients with primary liver cancer who were treated in our hospital from July 2012 to July 2019 were selected as study subjects, the patients were divided into observation group (n=52) and control group (n=48) according to the order of admission. The control group was treated with laparoscopic hepatectomy, and the observation group was treated with retetroxel on the basis of the control group. Serum CIART, AFP-L3, GP73, ALT, AST, TBIL, 1-year, 3-year, 5-year tumor recurrence rates and adverse reactions were compared between the two groups before and after treatment. RESULTS:Before treatment, CIART, AFP-L3, GP73, ALT, AST and TBIL levels were not significantly different between the two groups. After treatment, the levels of CIART, AFP-L3 and GP73 in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in serum ALT, AST and TBIL levels between the two groups (P>0.05). The 5-year recurrence rate in the observation group was significantly lower than that in the control group (P<0.05). There was no significant difference in the 1-year and 3-year recurrence rates between the two groups (P>0.05). The total incidence of adverse reactions in the two groups was 53.84% and 52.08%, respectively, with no significant difference (P>0.05). CONCLUSION:Laparoscopic resection combined with letetrexed in the treatment of primary liver cancer can effectively reduce the level of ciart, AFP-L3 and GP73, and it is safe.
